Embleema

📍 New York, United States🗓 Founded 2017👥 19 employees💰 Last funded Feb 2019
Hospitals and Health Care🌐 embleema.com
Website LinkedIn
Embleemas software platform brings precision medicine sooner to patients by collecting and generating regulatory-grade evidence. Our platform natively unifies clinical, molecular and real-world data and is the sole one used by the FDA for its regulatory evaluation of health products involving genomic datasets. The protocols and algorithms contained in our platform are also the basis for future CDISC standards for cell and gene therapies. The FDA also uses our platform to produce regulatory grade genomic sequences for SARS-CoV-2 and other microbial pathogens (project ARGOS). In addition to the FDA, our platform powers the Lupus Landmark Study, the largest clinical study for lupus in the world, the Human Epilepsy Projects and tens of other clinical studies for pharmaceutical companies, biotechs and patient groups. More than half of the top 10 Investigational sites in the US use our platform: John Hopkins, NYU, UCSF, Yale, UPenn, Washington University in St Louis, Cornell and many others also such as Mayo Clinic, Yale, Georgetown.
3
Total investors
3
Early stage
0
Mid stage
0
Late stage
2017
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
2
France
1
Investor activity2018–2019 · investors recorded per year
2018220191
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Embleema?
Embleema has 3 investors on record on gritt.io, including 3 early-stage backers.
When did Embleema last raise funding?
The most recent investment in Embleema recorded on gritt.io was in February 2019.
When was Embleema founded?
Embleema was founded in 2017.
What industry is Embleema in?
Embleema operates in Hospitals and Health Care. Find similar Hospitals and Health Care investors on gritt.io.
Where is Embleema based?
Embleema is headquartered in New York, United States.